Eli Lilly’s Retatrutide Cuts Knee Osteoarthritis Pain by Up to 75.8% in Phase 3 Trial
A Phase 3 trial reported that retatrutide cut knee osteoarthritis pain by up to 75.8%.
Related stories
Cogent Communications Reports $29.8M Third-Quarter Loss
M impact | EQUITY | Nov 05, 2026, 11:58 AM UTC
Wheels Up Experience Reports Third-Quarter Revenue of $164.8M
M impact | EQUITY | Nov 05, 2026, 11:57 AM UTC
Wheels Up Announces Third-Quarter Results
Wheels Up said its business transformation has reached an inflection point, with Signature fleets delivering the majority of an unspecified measure.
M impact | EQUITY | Nov 05, 2026, 11:57 AM UTC
US Foods Q3 Revenue Misses Estimates; Trims FY Sales View
M impact | EQUITY | Nov 05, 2026, 11:57 AM UTC
LSEG Agrees to Acquire Octus
LSEG agreed on October 22, 2026, to buy Octus.
M impact | EQUITY | Nov 05, 2026, 11:57 AM UTC
DHL Group Reports Higher Q3 Earnings as German Business Lags
DHL Group’s third-quarter earnings increased, while its German business lagged behind.
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC